Navigation Links
Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement. Under the agreement, Olympus Biotech International will have exclusive distribution rights for the BonAlive® granules product line in Germany, France and the UK. The product line covers regenerative products for orthopaedic and trauma surgeries.



The agreement is an important milestone in the commercialization strategy of the BonAlive® granules product line in the pathway of further expanding the access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons" said Dr. Fredrik Ollila , CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone".

"The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global assessment of different technologies and options we were impressed by the clinical evidence and clinical data available for BonAlive®. We are very much convinced to have decided for a partnership with the company having the right approach to improve patient outcome" said Florian Kemmerich , President of Olympus Biotech International.

For more information about BonAlive Biomaterials Ltd, please visit

For more information about Olympus Biotech, visit

About BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical devices for bone regeneration. The focus is to provide world-leading biomaterial solutions for the treatment of chronically infected bone. BonAlive® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional distributor network. The clinical use of BonAlive® is supported by a twenty year research history including several randomized prospective trials in the field of spine, benign bone tumor and trauma surgery. More than fifty peer reviewed articles have been published about BonAlive®.

About Olympus Biotech International Limited

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulates the intrinsic healing capacity in the living body. Olympus Biotech provides minimally-invasive regenerative therapies for bone and soft tissue including growth factors, scaffolds and cell harvesting technologies as well as tools for access, placement and delivery.

For questions or additional information, please contact:

Olympus Biotech International Limited
Dirk Dembski
Vice President Marketing and Business Development
Olympus Biotech International  
Mobile +49-172-2492700

BonAlive Biomaterials Ltd:
Fredrik Ollila , PhD
Chief Executive Officer
BonAlive Biomaterials Ltd
Mobile +358(0)400-931-209
Fax +358(0)421-917-744-00

SOURCE BonAlive Biomaterials Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Olympus Introduces the Worlds First and Only Monopolar, Disposable Tonsil Adenoid Debrider (DTAD)
2. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
3. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
4. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
5. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
6. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
7. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
8. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
9. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
10. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
11. Lifeline Biotechnologies Receives Third Software Patent
Post Your Comments:
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
(Date:10/13/2015)... DIEGO , Oct. 13, 2015  Nanomedical ... for use in research and diagnostics, announces the ... $1.6 million led by Serra Ventures. ... mission is providing low-cost, easy-to-use monitoring and diagnostic ... health decisions. The funding round will enable the ...
(Date:10/13/2015)... ) ... "US & European Markets for Shoulder Labrum ... to their offering. --> ... "US & European Markets for Shoulder ... report to their offering. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... PhyMed Healthcare Group , a ... partnership with WPC Healthcare , a provider of predictive analytics solutions for ... into an aggregated data repository necessary to perform reporting and analytics on selected ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article published ... that women who successfully lose weight with a bariatric procedure are much less likely ... The article notes that anywhere from 40 to 50 percent of all endometrial cancer ...
(Date:10/13/2015)... Laguna Hills, CA (PRWEB) , ... October 13, ... ... document management and workflow solutions, announced today their sponsorship of the Microsoft Dynamics ... in Reno-Tahoe, Nevada. AXUG Summit, GPUG Summit and NAVUG Summit are independent user ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a ... announced today a significant contract that will provide its award-winning private messaging solution ... on the growing success of its Relay program, IBX Wire™, which now has ...
Breaking Medicine News(10 mins):